K*hlékologie* 4B*1*B{+1{4{*p. 58-+4*

Fondements et objectifs de la commission Cos-C1s de la SFP.

Terms and objectives of the SFP commission on Cos-C1s.

Boisseau M.R.[1], Chardonneau J.M.[2]

Résumé

>('0[~(+B' l/X{ "X{ KXm~(P[tP["G4Gt[0G^X/ "K #(;#^5j({ '(P^X P(')05~('{ 9 a e6o ~(' j[0G(X0'p >(' ~^5P(5#';(GX(5'(' '^X0 a P[k['(~•5X([P0)#[0G^X(P[w5[PG0)~(;G(j(#'^XX(PP((0 '^tG[P(~(' '5N(0'{ #(X~[X0X)t("[G#(P(5#)#G'((X tD[#;(p @)[XU^GX'{P['j)tG4GtG0)~(t(;#^5j(~(j[0G(X0'{ '5# P(' jP[X' tPGXGw(0(jD>'G^j[0D^;)XGw5({#('0(~G't50)(p >[t^UUG"G^X[~ D^t ~(P[N4K~^G0(X0(#~(#)j^X~#(a jP5'G(5#'GX0(#)#[0G^X'p

s **Peut-on attribuer les douleurs aux veines à ce stade ?**

+(P['(UkP([tw5G' t^X'(X'5(PP(U(X0 lG~(X0G4Gt[0(j#)tG'(~(' '>Uj0`U('{ #);(#'GkGPG0)(' ~^5P(5#'{ 't^#(' ~(~G't#GUGX[0G)^X('(X'GkGPG0)mp

s **Les aspects cliniques se résument-ils à une seule forme essentielle ?**

>•(=jP^#[0G^)[X# jP)0D>'U^;#[jDG(G~(X0G4#e)w5(UU(X0 5X(;(GX^j[0DG(4^Xt0G^XX(P#?'(^tG)({ '5;;)#[X0 P•(=G'0(Xt(~•5X(4^Xt0G^X)[#G)0[P(~)4GtG(X0(p('(#(tD(#tD(' U)#G0(X0•*0(#)0(X~5(' j^5# ["^tG(# 5X 0(#[GX)[#0 Gt5PG5[6#'0[~(+B'p

s **Le mécanisme des douleurs est-il connu ?**

7P~(U(5#(^k't5#{ t(w5GX5G0 P•G~(X0G5)0[~(+B'p @)[XU^GX'5X(')w5(Xt(~•);)X(U(X0' ('0 G~(X0G4G P[j#("G^X D>~#^'0[0Gw5P(;)(GX~5G)X(D>j^=G(~(P[j[#^G (0 ~(' tG'[GPP(U(X0X^#U[5= ~5 4P5X;5GX a P[k['(~•[~D)'G^X~(P(5t^t>0(' a P•(X~^0D)PG[0G;) (0 ~(j(#U)[kGPG0)tt#5( ) [5 t^5#' ~(t(00(GX4P[UU[0G ['(j0Gw5('(U(00(X0(X jP[t(~(' j[0D<[>' ~•[t0G;[0G^X ~(' 4Gk#('+ [;G"[X0 t^UU(X^tGt(j0(5#' l#`P((X j[#0Gt5PG(#(P[k#[~>OGXGX(t^"[X^J~(' (0 ~5 @Bm[>(' 4Gk#('+)0(X~(X0 P(' GX4P5=^5P^5(5= l#)4P(=(~•[=^X(m~•^9 P[P^t[PG'[0G^X)Uj#)tG'((0 [X;^G"[X0(~(' ~^5P(5#'p

Summary

"tt*o#~ing* 0*o* ;*ein* ~*i*'*e*['*e* '5#;*e*>'{ *4-15 % of p*[0*ien*0' *kelong* 0*o*0*he*+/"K +*o*' t*l*[". >*o*<*e#limk p*[*in p#o*~5*te*' [~*e*0*e#io#*[0*ioim pe#'on*[*l* [*n*~ '*oti*[*l q*5[*li*0>*of life* [*n*~ *i*' 0*he #e*['*on p*[0*ien*0' '*eek* 0*#*[0*men*0. V*he*0*he*# 0*hi*' *ton*'0*i*050*e*' ['*petifit g#o*5*p of p*[0*ien*0' <*i*0*h* ['*petifit tlinit*[*l pit*05*#e* [*n*~ *ph*>'*iop*[0*holog*> *#em*[*in*' ~*ek*0[*kle*. "*n* [~ D^t *tommi*00*eeh*[' *keen* 'e0 5*p* k> 0*he* "*Notié*0*é* 4#[*nv*[*i'e* ~*e K*h*lékologie*" 0*o* 0#>0*o* [*n*'< *e*# '*e*;*e*#[*l q*5*e*'0*ion*'.

s ***Do the pains arise from the veins ?***

O*hi*' [*ppe*[#' 0*o ke gene#*[*ll*> [*g#ee*~ *follo*<*ing #eten*0 *ton*'*en*'5' *mee*0*ing*' *(*[tt5# [0*e* ~*e*'t#*ip*0*ion of* 0*he* '>*mp*0*om*'{ *#e*;*e#'ikili*0>*of* 0*hep*[*in*'{ ~*i*'t#*imin*[0*ing* '*to#e*').

s ***Is the clinical picture limited to this particular class (Cos) ?***

K*le*0*h*>'*mog#*[*ph*> *f#eq*5*en*0*l*> *#e*;*e*[*l*' [*kno#m*[*li*0*ie*' '5*gge*'0*ing* [~>'*f*5*nt*0*ion of* 0*he*;*eno*5' <[*ll*. 45#0*he*##*e*'*e*[#*th i' #eq*5*i#e*~0*o* ~*e*0*e#mine*<*he*0*he*#0*he*'*e th*[*nge*' [#*e* '*petifit* 0*otl*[" +B'.

s ***What is the mechanism of these pains ?***

O*hi*' *#em*[*in*' *ok*'t5# *e*{ <*hith le*[~' 0*o* ~*o*5k0 [*ko*50 0*he i*~*en*0*i*0>*of* 0*hi*' t*l*[". 6*o*<*e*;*e#*{ ['*eq*5*ente of e*;*en*0' *h*[' *keen i*~*en*0*ifie*~*t* #[*i'e*~ *h*>~#*o*'0[0*itp#e*"5#*e in* 0*he*;*ein*' *in*~5*te*' *h*>*po*=*i*[[*n*~ [*kno#m*[*l* '*he*[# '0#*e*"*e*' *on* 0*he*;*ein* <[*ll le*[~*ing* 0*o*[~*he*'*ion of le*5*kot*>0*e*' *on* 0*he*[t0*i*;[0*e*~ *en*~*o*0*heli*5*m* <*hith* k*etome*' *mo#e pe#me*[*kile*) 0*hi*' ['*ep*0*it infl*[*mm*[0*o*#> *#e*[t0*ion i*' ["*oti*[0*e*~ <*i*0*h* 0*he fo#m*[0*ion of p*[0*h*<[>' *of* [t0*i*;[0*ion of noti'tep*0*i*;*e* +-4*ik#e* (*p*[#0*t*5*l*[# *#ole of* k#[~>*kinin*{ *eto*'[*noi*~' [*n*~ @B).U*i*[[=*on #efle=e*'{ 0*he* +-4*ik#e*' '*p#e*[~ 0*he p*[*inf*5*l infl*5=*e*'{ <*hith e=pl*[*in*' 0*he* ;[*g*5*e lot*[*li*'[0*ion* [*n*~ ~*i*'0#*e*"*ing n*[05#*e of* 0*hep*[*in*'.

---

1. K*h*[#*m*[t*ologie*{ P*ni*;*e*#'*i*0*é* ~*e* **o#*~*e*[5= 4{ *1+8*{#5*e*>*éo*-N[*ign*[0{11B*+ **o#~*e*[5={ 4#[*nte*.
4. K*hlékologie*{P*ni*;*e*#'*i*0*é* K[#*i*' W77*5*{#5*e*~*e* *5~[*pe*'0{ *44*BBB@[*n*0*e*'{4#[*nte*.

I-m[*il* zUp#k^G"([5i<[X[~^^ p4#

"tt*ep*0*é le 1e#m*[#' 4B*1*B

0 P" GX;('0G;[0G^X'j[#)tD^;#[jDG(j^5#)05~G(# P•)j[G''(5# ~(P•D>j^~(#U('5'U[PP)^P[G#U)~G[P(

0 P" (=jP^#[0G^X')tD^F-^jjP(# j^5# U('5# (# P[t^UjPG[Xt(l#[jj^#0 ^#0D^'0[0G'U(,~)t5kG05'm-(;(GX(' j^jPG0)(' (0 ~(P[;#[X~(;(GX('[jD,X(~[X' '[j^#0G^X 4)U^#[P(p

+(00((Xw5*0(('0)0(X~5([5 '0[~(+e' ~(j#^kP)U[0Gw5(#^tD({ w5^Gw5(P5' X(00(U(X0GUjPGw5) ~[X' P[?U+{ ~5 4[G0-(P[j#)'(Xt(~('G;X(' ~5 0>j(0)P[X;G(t0['G('(0 ~(;[#Gt(' #)0Gt5P[G#('p

Les problèmes posés par la veinopathie Cos

>(' w5('0G^X'j^')(' j[# t('0[~('^X0 X^Uk#(5'({ ~•^#~#(tPGXGw5(j#[0Gw5((0 ~•^#~#(t^Xt(j05(Pp >(' '>Uj0`U(' j#^j^)' j[# P(' j[0G(X0' l'^5; (X0 ~(' j[0G(X0('m^X0 '^5; (X0GUj#)tG'(0 j^'(X0 5X j#^kP,U(~(~G[;X^'0G+G44)#(X0)0(P;GG'FaF;G-'(' ~^5P(5#'~(' U(Uk#(' GX4)#G(5#5'{0^501D(A P(' j(#'^XX('];)('p

+^UU(P(' ~^5P(5#' [5=w5(PP(' '^X0 t^X4#^X0)' P(' j[0G(X0' [P0,#(X0 P(5# w5[PG0)-(;G({ 5X(~^XX)(j'> tD^P^;Gw5(j#(X~ '^5; (X0 P(~('5'{ [;(t P[~G[P(t0Gw5(5[''Gw5(~(P[@j^5P((0 P•b54AzX('0Ft(j[' 5X)0[0~)j#(''G4 w5G0 aP•^#G;G>X(~^5P(5#"5jj^')(' ^5 ~('(X'[0G^X' w5['GX^#U[P(' U[G' [UjPG4G)(xpp

O^50 t(tG '(#[G0 #)'^P5 '•GP(=G'0[G05X(^5 ~(' (=jP^#[0G^X'U(00[X0(X);G~(Xt(5X(P)'G^X^5 5X(t[#[t0)#G'0Gw5(~(P•[#k#(;(GX(5= ~(' U(Uk#(' GX4)#G(5#X #[jj^#0 [;(t P[;(GX^j[0DG(+B'{ U[G' t(X('0 j[' P(t['{ (X P•[k'(Xt({ [5N^5#-•D5G{(~)tG'G^X t^X'(X'5(PP(p

"GX'GP(-^jjP(# ;(GX(5= [jj[#[l0 GtGt^UU(5X((=jP^#[0G^X^X4G#U[X0)5P(U(X0 ~(' ['j(t0' X);[0G4' '5# P(jP[X [X[0^UGw5(p

A. Dès lors peut-on être tenté de « négliger » ces formes de stade Cos et C1s ? La réponse est nettement négative pour un ensemble de raisons dont les suivantes :

1. Fréquence

>(')05~(' ~(j^j5P[0G^X' (0 P(' (Xw5*0(')jG~)UG^P^;Gw5(#)t(X0(' U^X0#X05X(**fréquence non négligeable** ~(P•[00#Gk50G(^Xj[0G(X0' [5 '0[~(+B'p +(00(4#)w5(Xt({ w5(P•^X)0[kPG0X j^5#t(X0[;(' ~(' j(#'^XX(')05~G)('{~)j(X~ ~(P[U)0D^~(50GPG2)(PP(('0 jP5')P(;)('G P•)05~(j^#0(~•[k^#~ '5# P(' '>Uj0`U(' t^UU(t#G0,#(-•(X0#)(~[X' P•)05~((0 jP5' k["(~[X' P(t[' ^9 P•GX;('0G;[0Gj^X0('5# P•['j(t0 ;[#Gw5(5=p(jP5'{ t(#0[GX(')05~(')jG~)UG^P^;Gw5(' X(0G(XX(X)[0 t^Uj0(~•5X'0[~(+B' 2

BXj(50 tG0(#P(' ~^XX)(' '5G;[X0('{ w5G3^X0 t(j(X~[X0 ~(' (=0#f^P[0G^X' (X t(w5G1^Xt(#X(~(')05~(' ~(#)4)#(Xt(' [X0)#G(5# aP•GX95t0G^X-(P[tP["G4Gt[0G^X +/"K z

0 M/>74 N05~>4BB4z9o p1q)

0 +M/O/ N05~>4BB1zBo p9q)

0 U/7@N N05~>4BB9z1{- o p6q)

0 N"@-7/5 B N05~>4BB6ze6{6o p+q)

0 @+7/ '05~>{ 6([P0D N0[05' GX'>Uj0^U[0Gt 4(U[P(' 4BB6z9{6o p*q)

0 *P>5"M7"@N05~>4BBZz* o p-qp

2. Pronostic

NG^X #(t^XX[I0 5X X^Uk#(X^X X);PG;([kP(~(j[0G(X0' +B' ~[X' P(t[~#(~(P[?U+{ t(P['5jj^'(w5(P•^X [tt(j0(P•G~)(w5•GP5G"(X0);^P5(# ;(#' ~(' '0[~(' a **manifestations cliniques** [tt^Uj[;X)(' ~•œdèmes ^5 ~(**lésions variqueuses**p

+(tG('0 X)[XU^GX'5X(D>j^0D,'({ t[# P(' '0[~(' +/"K X('('5tt,~(X0 j[' ^kPG;[0^G#(U(X0 ^X X(j(50 w5[PG4G(#50[5 U^GX'[5N^5#-•D5G-t(' '0[~(' t^UU(~(' @0[~(' j#)t^t(' Ap

7P4[50#(t^XX[I0#(w5•G(P=G'0(5X j[#[~^=(~(j[0G(X0' j#)'(X0[X0 ~(' '>Uj0`U('{ ~^5P(5#' ~G0(';(GX(5'('{ U[G' '[X' U[P[~G(;(GX(5'(G~(X0G4G[k^P(jj^'G0G^Xa ~•[50#(' j[0G(X0' j#)'(X0[X0 5X '0[050 ;[#Gw5(5= j#^X^Xt) GX~^P^#(p

+(tG#(X~P(PG(X0#(~^5P(5#'(0 #G'w5(~(~);(P^jj(# ~(' ;[#Gt(' (Xt^#(jP5' D>j^0D)0Gw5(P3X j(50 GU[;GX(# lt(w5G#('0(a ~)U^X0#mw5(t(;#^5j(~(j[0G(X0' #(j#)'(X0(5X t^PP(t0G)#0Gt5PG[;(t 5X U)t[XG'U(~G44)#(X0p

@)[XU^GX'{^X ('0 ^kPG;)~(t^X'G~)#(# t(' j[0G(X0' ~[X' P[j(#'j(t0G;(~•5X( );^P50G^X;(#' 5X)0[0 ;[#Gw5(5=(0 ~•GX'0G05X(X0#G0(U(X0-(j#);(X0G^Xp

PX[50#(['j(t0 ~5j#^X^'0Gt('0 P•[P0)#[0G1)X G4('0(~(P[qualité de vie{ (X j[#0Gt5PG5# P(jP[X j#^4("G^XX(P (0P['0[0G^X-(k^50 j#^P^X;)(p

B. Parmi les nombreuses interrogations que pose la veinopathie algique Cos, trois questions ont été choisies faisant partie en priorité des objectifs de la commission :
– la difficulté de l'*attribution des douleurs* aux veines ;
– la définition de *formes cliniques* ;
– et enfin l'approche actuelle, et en large partie prospective, des *mécanismes des douleurs*.

1. L'attribution des douleurs

>•G~(X0G4Gt[0G^X>Uj0`U(' (X #(P[0G^X(t P•[#k#(;(GX(5= '5j(#4GtG(P#(j^'('5# 5X(**nomenclature homogénéisée** t^X'(X'5(PP(U(X0) t(P[[ )0) #)[PG')a j[#0G#(0#[5=)jG~)UG^P^;Gw5(0 ~(~)X^UGX[0G^X' (X P[X;5([X;P[G'(p

Terme anglais	Terme français
Heaviness peq	^5#~(5#' ~(N[Uk('
Swelling l4((PGX;4m<G0D{G0D^50~(U[[0 0D([XOP(p4q	(X'[0G^X~(;^X4P(U(X0[;(t ^5 '[X' b~,U(a P[tD(;GPP(m
Pain {"tDGX;l~5PP([~> j[GXnp9q	^5P(5#'{~^5P(5#''^5#~('{ jDP)k[P;G('
Cramps lU5'tP('m	+#[Uj(' lU5't5P[G#('m
Itching	-)U[X;([G'^X{ j#5#G0
Burning p1q	(X'[0G^X~(k#7P5'# l'^5; (X0[''^tG)([5 j#5#G0m
Tingling lGXtP5~Gj[#('0D('G['m	KGt^0(U(X0lGXtP5[X0^5#UGPP(U(X0{^5#~G''(U(X0 (0 j[#('0D)'G(m
Tired legs lP(;F0G#(~X(''m4[0G;5(	N(X'[0G^X(4[0G;5(~[X' P(' N[Uk('
Throbbing lt[P4m	N(X'[0G^X(j5P'[0G^X{-•)P[Xt(U(X0 lU^PP(0m
Restless legs l~[> 0GU(p6q	[lUk(' '[X' #(j^' lj(X~[X0 P[N^5#X)(m
#[~k5#>{ eZZZ(0 4BBB) =[DX{4BB9) 7'[[t{ eZZ6) >[X;(#{ 4BB6)M/>7/4 N05~>) =(X~P(#{4BB) /OP^{4BBZp **Score de Carpentier** pZqtP[''(U(X0 ~(ea 6 ~(P[j(#4^#U[Xt(~(' 'G;X('p >•(X'(UkP([N^50)a P•[;;#[;[0G^Xj[# P[tD[P(5# (0 [k'(Xt(~•[;;#[;[0G^X j[# P[U[#tD([00(GXZ6 o ~(~G't#GUGX[0G^X o ~('(X'GkGPG0)p **Facteurs associés en faveur de la MVC** peq~^5P(5#'[5;U(X0)(' j[# P[tD[P(5#{ P['0[0G^X-(k^50 j(X~[X0 P[N^5#X)({ '^5P[;)(' j[# P(#(j^' ~(U(Uk#(' GX4)#G(50;^5 P(5#)P);[0G^Xp	

TABLEAU 1 : Liste et valeurs de 10 symptômes de la maladie veineuse chronique (MVC).

>(**Tableau 1** #[jj^#0 (t(')05~(' w5G3X0#(0(X5eB0(#U(' [5=w5(P' G#[50[~D)#(#{t•('0FaF~G#(5•G4P500(X~#(a X(X^0(#w5(t(5=FPa(X P(' 4[G'[X0)X^Xt(# j#)tG')U(X0 j[# P(' U[P[~('p

+(P[('0 #(j#G'~[X' 5X(j5kPGt[0G^X)t(X0(t^X~5G0[[# /OPa4p4qp(jP5'{ t(#0[GX(')05~(' ^X0 j(#UG' 5X(@t^0[0G^X~(' '>Uj0`U(' ~(ea 6 ~[X' P(5#(#4^#U[Xt( )"'^tG)' a P•[k'(Xt(~•[;;#[;[0G^X j[# P[U[#tD(t(' (X'(UkP(' [##G;(X0{^5# P•[00#Gk50[5=X;(GX('{ a 5X(~G't#GUGX[0G^X6 o (0*6 o ~('(X'GkGPG0)qp

Ainsi un « corpus » de diagnostic de veinopathie algique Cos peut être énoncé, provenant des études des symptômes relevés suivant la nomenclature :

0 '>Uj0`U(' [tt(X05)' j[# P['0[0G^X ~(k^50 j#^P^X;)({ [5 45#(0 a U('5# (~(P[N^5#X)(j[# P(jG)0GX(U(X0)

0 X•(X0#X[X0 j[' ~(k^G0(#G(

0 j P5' [tt(X05)' (X j)#G^~(('0G;[P({j[# P[tD[P(5#{ P[j)#G^~(j#)U(X'0#5(PP(~(P[;#^"'("( )

0 ~GUGX5)[# P(#(j^' (0 '5#0^50P['5#)P);[0G^X~(' U(Uk#(')

0 U[#tD(GX~G44)#(X0[G' '5#0^50 X^X [;;#[;[X0( ) t(j(X~[X0 (PP(^5P[;(P(' '5N(0' j#)'(X0[X0 P('>X~#^U(~(' N[Uk(' '[X' #(j^')

0 ~GUGX5)[# P[t^Uj#("G^X (0 P(' U)~Gt[0G^X;(GX^F [t0G;('p

-(5= #(U[#w5(' X)[XU^GX'z5X@4^X~~^5P^5{5= Aj(50 *0#{ j#)'(X0 l@[*thing* An) ~(jP5'{ P('>X~#^U(~(' N[Uk(' '[X' #(j^' j(50 t^Xt(#X(# 5X'>X~#^U(X(5#^P^;Gw5('j)tG4Gw5(t[#[t0)#G') j[# ~(' U^5; (U(X0' #>0DUGw5(' j(X~[X0 P('^UU(GPp

>['>Uj0^U[0^P^;G(GtG#(0(X5(t^Xt(#X('5#0^505X([;G0[0G^X-(' N[Uk(' j(X~[X0 P[N^5#X)({[5 #('0[5#[X0{ (0tppp

2. *Le problème des formes cliniques*

4[50(~•(=[U(X t^UjP)U(X0[G#({ t(' ['j(t0' tPGXGw5(' '^X0 ~^Xt a t^X'G~)#(#t^UU(5X(**forme essentielle**{ 5XGw5(U(X0[')('5# P•(=G'0(Xt-('>Uj0`U('p

BX j(50 > [N^50(#~,' a j#)'(X0 5X(**forme essentielle dépressive** [;(t [P0)#[0G^X-(P[w5[PG0)-(;G((X '•[jj5>[X0 '5# P•)05~(~(=(X~P(#[>[X0 [jjPGw5) P(w5('0G^XX[G#(N4Fe4 a 5X(t^D^#0(~(j[0G(X0(' j#)'(X0[X0 ~(' ~^5P(5#';(GX(5'(' peBqp

>(k50 t(j(X~[X0 ('0 ~(j^5; ^G#GXt^#j^#(#P(' j[0G(X0' ~[X' 5X t[~#(jP5' j#)tG'{ t(P5G~(' **phlébopathies fonctionnelles**p /PP(' '^X0);G~(X0(' ~[X' P(t[' ~(0#5kP(' ~5' a 5X(4^#0([P0)#[0G^X-5 #(0^5#;(GX(5= lGX'544G'[Xt([#~G[w5({ #('jG#[0^G#({4^#0([X^U[PG(' j^'05# ^P^;Gw5('{ j(#'^XX('];)('{ t^Uj#("G^X' 05U^#[P('mp

PX 0#[GPGX[5;5#P ('0 t(P5G~(?[5#Gt(+P^[#(t (0 [Pp{ G~(X0G4G5X0@>*n~#ome p#é*;[#*iq5e5*=A peeqp[P•[;G0 '5#0^50 ~(4(UU(' N(5X(' tD(A P('w5(PP(' P[jP)0D>'U^;#[jDG(U(0 (X);G~(Xt(5X([5;U(X0[0G^X~(P[~G'0(X'GkGP;G0X)(5'(p

+(00(G~)([ )0) #(j#G'(jP5'G(5#' 4^G'[k^50G"[X0 a P[t^Xt(j0G^X ~•"PP(;#[(0 ~•"X~#(^AAG-(**phlébopathie hypotonique**p+(' t^Xt(j0' '^X0 GX0)#("[X0' (0 U)#G0(X0 ~•*0#{ #(tD(#tD)'{ ~•[50[X0 w5(P•^X t^XX[l0 P•(=G'0(Xt(~(**troubles structuraux génétiques de la paroi veineuse liés à une dysfonction du tissu collagène**p



FIGURE 1

?[G' P(j#^kP,U(('0 w5(P[jP)0D>'U^;#[jDG(X<('0 jP5' (UjP^ >)((X ~(D^#' ~(' t(X0#(' ~(#(tD(#tD(ppp

M[jj(P^X' X)[XU^GX'{t^UU(~GJP5' D[50{w5(+B' ('0 t^X'G~)#) t^UU(j#)t5#'(5# ~5 +1 jP5' w5(~5 +4 lb~,U(' jP50`0w5(;[#Gt('mp

3. Mécanisme des douleurs veineuses

>[jD>'G^j[0D^P^;G(~(P[~^5P(5##[00[tD)([5= t^X~5G0' ;(GX(5=~(' U(Uk#(' GX4)#G(5#X('0 j[')P5tG~)(~(U[XG,#(j#)tG'(p BXt^XX[l0X)[XU^GX'5Xt(#0[GXX^Uk#(~(j^GX0'[>[X0 0#G0a P•^#;[XG'[0G^X(5#^P^;Gw5(0 a '[UG'((X N(5p

Depuis les travaux d'Arndt{ ^X '[G0 w5(P•GX4P5= ~^5P^5(5= ('0 #(t5(GPP(0 0#X'UG' j[# P(' **fibres C amyéliniques**{ ;^G(' [44)#(X0(' ~5 **système nerveux périphérique**{ [>[X0 P(5#' t^#j' t(PP5P[G#(~[X' P(' ;[X;PG^X' #[tDG~G(X[G"[X0 t^UU(**nocicepteurs** [5 XG;([5 ~(P(5#'[=^X(' 0G"5P[G#('p

PX0#[GP(X UGt#^'t^jG( )P(t0#XGw5[U^X0#)w5•(PP(')0[G(X0#)'(X0('{ U[G' j(5 X^Uk#(5'('{ ~[X' P[j[#0G((=0(#X(~(P[U)~G[[5 t^X0[t0 ~(P•[~;(X0Gt(e4qp

7P[jj[#[l0 w5(P(' GX4P5=X0 [5"G #(t5(GPP(0X ~(D^#' ~(' ;(GX(' ~[X' P(0G"5t50[X) (0 '^5'Ft50[X) [5 XG;([5 ~(' P^;(' '[jD,X('p >[t^#X(j^'0)#G(5#(~(P[U^(PP(#(v^G0P(' ~(X~#G0(~(' 4Gk#('+{ ^9 GP"(0#5; (X0 (X t^Uj)0G0G^X(t t(5= ~(' 4Gk#(U>)PGXGw5(P(;[X0P(')P)U(X0' ~5 0^5tD(#{~(' jGw7(# (0 ~(P[0(Uj)#[05#(p

>(@g[0e ton0#bl A U^~5P(P•[tD(UGX(U(X0-(' GX4P(5= ~^Xt ~(' '(X'[0G^X' ~^5P^5(5'(' ;(#' P(' t(X0#(')0[;)' ~(P[U^(PP(5G' ;(#' P(t^#0(= **(Figure 1)**p

>•[t0G;[0G^X(' X^tGt(j0(5#' ('0 ~G't50)(ppBX '[G0w5(t(P[X(j(50 *0#(5XGw5(U(X[# ~G'0(X'G^X)t[XGw5(~5 t^X~5G0(GX(5=t[# t(P5GF(0 P[#;(U(X0 GX'(X'GkP(P[~GP[0[0G^X(X GX0(#U)~G[G#(GUGw5(('0 ~^Xt X)t("[G#({ #(j#)'(X0) j[# P**activation aseptique de l'endothélium et des éléments figurés du sang**p

BXj(50 PG'0(5X(')#G(~(')w5(Xt(' ~•[t0G;[0G^X

• **L'augmentation de la pression hydrostatique** (X j^'G0G^X(k^50 ('0 P(jD)X^U,X(~(k['(w5G#)'G~(a P[UG'((X N(5~(' U)t[XG'U(' ~(' ~^5P(5#'{t^UU(GP ('0 ~•[GPP(5#(t^XX5t^UU(4[t0(5#j#^;^w5[X0 a0(#U(P•[jj[#G0G^X(' ;[#Gt(' (0 P(#(4P5=p^X[t0G^X)#GXtGj[P(('0 ~(j#^;^w5(# 5X('0['(;(GX(5'(p >•(44(0~(P[j#("G^X j(50 *0#(#("(X0G j[#0Gt5PG,#(U(X0 4[G0-(P•(=G'0(Xt(~(0#5kP(' ~(P•(X;G#^XX(U(X0(GX(5= [50^#G'[X0P[;(GX(a '(~GP[0(#[;[X0[;(p

s >[**stase des veines superficielles** ~(' U(Uk#(' GX4)#G(5#[(5X'Gt^X'0G05)({ j[#4^G' 4[;^#G')(j[# 5X(~G44Gt5P5)#(0^5#;(GX(5={;[j#^;^w5(# 5X(**hypoxie** '(~);(P^jj({ [GX'Gw5•5X([P0)#[0G^X(' **cisaillements** ~5 4P5a P[j[#^Gp>•(X~^0D)PG5(0 [P^#' [t0G;) (0 (=j#GU(~(' U^P)t5P(' ~•[~D)'G^X j^5# P(' P(5t^t>0(' lU+"? { 7+"? m(0 5X(t['t[~(~(j#^~5G0'~•GX4P[UU[0G^Xp

s K[#UG(5= ~5 K"4[t0G;[X0P(' ;P^k5P(' kP[Xt' tG#t5P[X0'{ ~5 U/54 [5;U(X0[X0 P[j(#U)[kGPG0)-5 ;[G"([5 lt(w5G GX0#5G0(' j#^0)GX(' jP['U[0Gw5(' '^5' P•(X~^0D)PG5Um ~(')t^'[X^J~(' 0(P'w5(P[K5/4{ ~(' t>0^OGX('p

s >(' P(5t^t>0(' [~D)#(X0' (0 #(0(X5' I<*hi0e tell* 0#*pping* m ')t#,0(X0 ~(X^Uk#(5= j#^~5G0' GX4P[UU[0^G#(~{X0P•DG'0[UGX((' P(5t^0#G,X('p>(' D)U[0G('4^5#XG"(X05@B[#UG~•[50#(' '^5#t('p



VCAM, sélectines : molécules d'adhésion ; MMP : métalloprotéinase ; TGFβ1 : facteur de croissance ; TNF, IL : cytokines ; PK A et C : protéines kinases ; ASIC : recepteur neuronal ; P2X3 : récepteur purinergique ; CGRP : *calcitonin gene related peptide* ; TTXr, VR-1 : canaux de dépolarisation ; GDNF : *glial derived neurotrophic factors.*

FIGURE 2

s " j[#0G#-(t(' j#^~5G0'~(' **voies d'activation des nocicepteurs** '(U(00(X0(X jP[t(z[GX'G-5 OGXGX^;,X({ ~•^#G;GXP['U[0Gw5({ ('0 'tGX~) (X OGXGX[5 t^X0[t0 ^5 '^5' P•(X~^0D)PG5U#UG (PP(' '(4^#U(P[k#[~>OGXG=(mw5G(PG(~(')t^'[X^J~(' lK5/4m(0 [5 @B j^5# [t0G;(# P(' #)t(j0(5# *4 ~(P[*= ~(' X^tGt(j0(5#' P(' jP5' j#^=GU[5=KP5'G(5#[0h<[>' ^X0)0) [GX'G-)t#G0'["^tG[X0 P[*= (0 P(@Ba ~(' t^#j' t^UU(P(t5? K^5 ~(' jD^'jD^PGj['('p +(' ;^G(' '^X0 ~(;G(t^5#0(le6 a 1B'(t^X~('mp

s PX(4^G'[t0G;)' P(' X^tGt(j0(5#' ~);(P^jj(X0 (5=F U*U(' 5X(**auto-activation neuronale** j[# ')t#)0G^X~('5k'0[Xt(K^5 ~(+5MK(0)0(X~(X0P['(X'GkGPG'[0G(X ~•[50#(' X^tGt(j0(5#' l#)4P(=(~•[=^X(m{P(' ~^5P(5#' ~(;(X[X0 [GX'GU[P P^t[PG')(' (0)0(X~5(' a 5X([G#(P[#;(p

s " 5 0^0[P(' j#^t("5' kG^tDGUGw5'(X0 X^Uk#(5=(0 t^UjP(=(' **(Figure 2)**p

s BXj(50 '^5PG;X(#P[U5P0GjPGt(0)#^t("5' (X0#X0 ~[X' P**activation neuronale** (0 P•GX0#Gt[0[3(t X ~(' j#^t("5' (X0#X0~[X' P(**remodelage** ~(P[j[#^G{'^G0P[UG'((X N(5~(4[t0(5#' ~(t#^G"[Xt(lO54βem{(U)0[PP^ j#^0)GX['(' l?? KZb 1mp

s - ,' P^#"(j^'(P[w5('0G^X~('[;^G# 'Gt(')jG'^~(' ~^5P^5(5= X(t^X'0G05(X0j[' 5X @0[#0(# A a P•[jj[#G0G^X~(' j#^t("5' ;[#Gw5(5=p+(P['(UkP(t(j(X~[X0 a ~)U^X0#(# t[# P(#(U^~(P[;('•GX'0G05(~•[k^#~ ~[X' P•(X;G#^XX(U(X0(' ;[P;(' (0 X('0 j[' ~^5P^5(5=p

Au total les douleurs de la veinopathie Cos ne sont pas d'ordre infectieux, ni allergique, peut-être sont-elles éloignées du *remodeling* ; elles sont réversibles du fait de la vie courte des processus biochimiques et constituent un caractère spécifique à l'affection.

La commission souhaite confirmer ces données en mesurant des marqueurs, type VCAM, en étudiant le rapport à la constitution des varices et de manière générale en réétudiant les schémas ci-dessus proposés.

Conclusion

>•GUj^#[X0(j#);[P(Xt(~(' N[Uk(' P^5#('{ P(5#' #)j(#t5"G^X' '5# P[w5[PG0)-(;G(~(UGPPG^X'(j(#'^XX(' (X 4^X0[5Xj#^kP,U(~('[X0) j5kPGw5(-^X0P(j#GXtGj[P'k'(#; [0(5# ('0 **le phlébologue**p

>•)05~(~(' U[P[~(' (X0#X0~[X' P(' '0[~(' +B' (0+e' ('0 #GtD{-(j(#'j(t0G;(' zUG(5=t[~#(# P(' 4^#U(' tPGXGw5('{ UG(5=t^Uj#(X~#(P(' U)t[XG'U('{ U(00# (X jP[t(~(' GX;('0G;[0G^Xt^UjP)U(X0[G#('p 0;(X05(PP(U(X0{t(P[j(50 t^X~5G#(a t^X'G~)#(#w5(P•^X[[44[G#(a 5Xt^PP(t0G4 j[#0Gt5PG-(#j[0G(X0'p

-(jP5'{ P(' ['j(t0' 0D)#[j(50Gw5(''^X0 a ~);(P^jj(# z ^X '[G0~)Naw5(P[t^Uj#(''G^X [;G0(X [U)PG^#[X0P(#(0^5#;(GX(5=(0 ~^Xt [tt(X05[X0 t[#[t0,#(#);(#'GkP(~(' j#^t(''5' kG^tDGUGw5(•[t0G;[0G^X0 4[;^#G'[X0P(*g*[0*e* t*on*0#*bl* ~(' GX4P5Gk#(+p

-(U*U({ P(' **médications veino-actives** ^X0F(PP(5X(jP[t(j#G;GP);G)(-5 4[G0~(P(5#[t0G^X ~•[X0[P;Gw5(;(GX(5=p

/X4GX{4^#0 ~(P•[X[P>'(~5 w5('0G^XX[G#({-•[50#(' [jj#^tD(' 0D)#[j(50Gw5(' (X #[jj^#0 [;(t P•(X'(UkP(~(' 'G;X(' tPGXGw5(1('UU5X' X^X ;(GX(5=[>[X0 5X(#)j(#t5''G^X '5# P('>'0,U(;(GX(5=j^5##^X0j(50F*0#(X^5' [jj[#[I0# (GX0)#(''[X0(' a U(00# (X b5;# (p

Références

ep/OP^4 *{ [~ D^t t^UUG00((p M(;G'G^X^4 0D(+/ ''K tP[''G4Gt[0G^X4^# tD#^XGt;(X^5' ~G'^#~(#'z t^X'(X'5' '0[0(U(X0p<pU['tp N5#p 4BB9) 9Bze49-F64p

4p /OP^4p{ (0 [PpPj~[0(~ 0(#UGX^P^;>GXtD#^XGt;(X^5' ~G'^#~(#'z 0D(U(GXO(#U O#[X'[0P[X0Gt7X0(#~G'tGjPGX[#> +^X'(X'5' -^t5U(X0'p <pU['tp N5#p 4BBZz9Z z9Z-F6Bep

1p <[X0(5p M(PG(405~>z 4G#'0^X'^PG~[0(~/5#^j([X ~[0[p ''X;G^P^;>4BBB) 6ez1eF*p

9p5G[XX^5O['"p-p{ (0 [Pp+PGXGt#[P(X0[0G^X[X~ [X[0^UGt ~G'0#Gk50G^X +U7 ^4 0D(P^<(# PGUk'GX[0>jGt[P ?(~G0(#[X([X j^j5P[0G^Xp7X0[X;G^Pp4BB4) 4eze-*FZ4p

6p=[DXNpM[0 [PpM(P[0G^X'DG[0<((X tPGXGt[P''G4Gt[0G^X ^4+U- [X~ j[0G(X0#(j^#0(~ w5[PG0^4PG4#(z'5P0'4#^U[X GX0(#X[0G^X[P^#0 '05~>pU/7@N N05~>p<pU['tp N5#p 4BB9) 1Z z-41F-p

+p >[X;(# Mp-p{ (0 [PpM(P[0G^X'DG[0<((X '>Uj0^U' [X~ ;(X^5' ~G'(['(p OD(N[X -G(;^ j^j5P[0G^X '05~>p"#tDp 7X0(#X0~p 4BB6) e+6ze94BF9p

*p 55(= <p<p0 [Pp+D#^XGt;(X^5' ~G'([']z D([P0D0[05' ^4 j^j5P[0G^X[X~ t[#(GUj[t0 ^X 0DGD([P '0[05' 0D#^5;D w5[PG0^4PG4(5('0G^XX[G#(7X0[X;G^Pp4BB6) 49 z46-F+9p

-p Z[D[#G(; Op{(0 [PpK#(;[P(Xt(^4 j#GU[#>tD#^XGt;(X^5' ~G'([']z 0D(*5P;[#G[X(=j(#G(Xt(p 7X0[X;G^Pp4BBZ) 4- z 1B1FeBp

Zp+[#j(X0G(#Kp{(0 [PpK#(;[P(Xt({ #G'O4[t0^#' [X~ tPGXGt[P j[00(#X' ^4 tD#^XGt;(X^5' ~G'^#~(#' ^4 P^<(# PGUk'z[j^j5P[0G^Xk['(~ '05~> GX4#[Xt(p<pU['tp N5#p 4BB9) 9Bz +6BFZp

eBp =(X~P(?#p{ 6[[' /p N5kN(t0G;{((X^5' '>Uj0^U'z #(;G(< [X~ j#('(X0[0G^X ^4 jGP^005~>pKDP(k^P>UjD^P^;>4BB*) e9z*9FZp

eep+P^[#(t ?p{(0 [PpPj~[0(^X 45Xt0G^X[P(X^5' GX'544GtG(Xt>p KDP(k^P>UjD^P^;>ZZ*) 1 z1FZp

e4p UG0[P{ *^G''([5 ?pMp{(0 [PpPXU>(PGX[0(+ 4Gk(#'[X~ GX4P[UU[0^#(PP'[#(j#('(X0 GX0D(<[PP^4D5U[X ;[#Gt^'(;(GX'p " tPGXGt^PK(^P^;Gt[P05~>p WU7/^#P~+^X;#(" PXG^X7X0(#X[0G^X[P((KDP)k^P^;G4BBZ) ?^X[t^{ ''5;5'0 1eFN(j0(Uk(#9{4BBZ) jp 96p